Compare NHP & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHP | SLDB |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2012 | 2017 |
| Metric | NHP | SLDB |
|---|---|---|
| Price | $16.46 | $9.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $16.36 |
| AVG Volume (30 Days) | 531.0K | ★ 970.1K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.09 | 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,279,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.68 | $3.79 |
| 52 Week High | $17.46 | $11.45 |
| Indicator | NHP | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 56.34 |
| Support Level | $14.54 | $6.25 |
| Resistance Level | $17.17 | $11.45 |
| Average True Range (ATR) | 0.78 | 0.45 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 59.11 | 95.89 |
National Healthcare Properties Inc is a publicly registered real estate investment trust. It is focused on acquiring, owning, and managing a diversified portfolio of healthcare real estate assets focused on senior housing operating properties (SHOP) and outpatient medical facilities (OMF) in the United States. The company operates in two reportable business segments: SHOP and OMF. The SHOP segment consists of assisted living communities, memory care communities and independent living communities, which are focused on needs-based assisted living and memory care. The OMF segment consists of physicians' offices and examination rooms, hospitals, pharmacies, hospital ancillary service space and other outpatient services. The majority of revenue is derived from the SHOP segment.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.